Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis
International Journal of Molecular Sciences · 16.08.2025 · 26 (16) · 7913
DOI: 10.3390/ijms26167913 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.08.2025. Verfasst von Dinesh Thapa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Curtin Medical Research Institute, Curtin University, Perth, WA 6102, Australia. Hauptthemen laut MEDLINE: Cannabidiol, Cyclosporine, Colitis, Mesalamine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Little Green Pharma, Little Green Pharma Ltd., Perth, Australia.
Abstract (Originalsprache)
Current therapies for inflammatory bowel disease (IBD), such as olsalazine and cyclosporine, often exhibit limited long-term efficacy and are associated with adverse effects. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, shows promise for its anti-inflammatory properties, though its effectiveness as a monotherapy remains inconclusive. This study investigates the therapeutic potential of combining low-dose CBD (10 mg/kg) with olsalazine (50 mg/kg) or cyclosporine (2.5, 5 mg/kg) in dextran sulphate sodium (DSS)-induced acute and chronic colitis models in mice. Disease severity was assessed via disease activity index (DAI), colon morphology, cytokine and chemokine expression, myeloperoxidase (MPO) activity, systemic inflammatory markers, and glucagon-like peptide-1 (GLP-1) regulation. Safety evaluations included haematology and plasma biochemistry. DSS-treated mice showed elevated DAI scores, colon shortening, heightened inflammation, and organ enlargement. Combination therapies significantly ameliorated colitis, reducing DAI, MPO activity, and inflammatory cytokines, while restoring colon length and GLP-1 levels—without inducing liver or kidney toxicity. These findings demonstrate that combining a low dose of CBD with standard IBD drugs enhances therapeutic efficacy while minimizing side effects, supporting its integration into future combination strategies for more effective and safer IBD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Curtin Medical Research Institute, Curtin University, Perth, WA 6102, Australia.
- College of Science, Health, Engineering and Education, Murdoch University, Perth, WA 6150, Australia.
- Harry Perkins Institute of Medical Research, QEII Medical Centre for Medical Research, The University of Western Australia, Nedlands, WA 6009, Australia.
- Department of Medicine and Surgery, University of Parma, 43125 Parma, Italy.
- Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research and Centre for Medical Research, The University of Western Australia, Nedlands, WA 6009, Australia.
ORCID-Profile: Dinesh Thapa, Rodrigo Carlessi, Marco Falasca
Förderung
- Little Green Pharma
- Little Green Pharma Ltd., Perth, Australia
Zitieren
APA
Thapa, D., Patil, M., Warne, L. N., Carlessi, R., & Falasca, M. (2025). Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis. International Journal of Molecular Sciences, 26(16), 7913. https://doi.org/10.3390/ijms26167913
Vancouver
Thapa D, Patil M, Warne LN, Carlessi R, Falasca M. Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis. International Journal of Molecular Sciences. 2025;26(16):7913. doi:10.3390/ijms26167913
BibTeX
@article{Thapa2025,
author = {Thapa, Dinesh and Patil, Mohan and Warne, Leon N and Carlessi, Rodrigo and Falasca, Marco},
title = {Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {16},
pages = {7913},
doi = {10.3390/ijms26167913}
}
EUVIMED